Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
PHASE1
The primary objective of the study is to evaluate the safety of idelalisib ...
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
PHASE2
The primary objective of the study is to determine the efficacy, as measure...
Status
Completed
Location
Birmingham Hematology and Oncology Associates, LLC
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab
PHASE2
Investigational Drug:
Ofatumumab (Azerra)
Route of Administration:
Intra...
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
PHASE2
This is a single-arm, Phase II study designed to enroll and treat up to 64 ...